Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

8.320 -0.230 (-2.69%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Expert Ratings For Intellia Therapeutics
Within the last quarter, Intellia Therapeutics (NASDAQ:NTLA) has observed the following analyst ratings: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 0 1 1... 
Via Benzinga
Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics Launch New CAR T-Cell Company
From Blackstone
Via Business Wire
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
Exposures Product Safety
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions. Earnings prints from big name... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 11, 2021
Upgrades Barclays upgraded the previous rating for Ventas Inc (NYSE:VTR) from Equal-Weight to Overweight. In the first quarter, Ventas showed an EPS of $0.72, compared to... 
Via Benzinga
What's the Best Way to Invest in Genetics Stocks?
Here are some of our experts' favorite gene editing plays for the long run. 
Via The Motley Fool
This Genetics Stock Could Have a Bright Future
Here's one genetics play that you might want to put on your radar. 
Via The Motley Fool
Biotech Stocks Cruise Through The Volatility
The XLV Healthcare Select SPDR is up 10% YTD. 
Via Talk Markets
10 Health Care Stocks Showing Unusual Options Activity In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Intellia Therapeutics, Inc. (NTLA) Q1 2021 Earnings Call Transcript
NTLA earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Benzinga's Top Ratings Upgrades, Downgrades For May 7, 2021
Upgrades Loop Capital upgraded the previous rating for Roku Inc (NASDAQ:ROKU) from Hold to Buy. In the first quarter, Roku showed an EPS of $0.54, compared to $0.45 from... 
Via Benzinga
The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2021
Upgrades For Genuine Parts Co (NYSE:GPC), Goldman Sachs upgraded the previous rating of Sell to Neutral. In the first quarter, Genuine Parts showed an EPS of $1.50,... 
Via Benzinga
3 Exciting Biotech Stocks to Buy Right Now
Gene therapies could be poised to enter an era of extraordinarily rapid advancement. 
Via The Motley Fool
CRISPR Stocks: The Big Analyst Call Destroying CRSP, NTLA, EDIT Stocks Today
A "sell" rating is one thing, but a 50% price target? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it. 
Via InvestorPlace
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
< Previous 1 2
...
11 12 13 14 15 16 17 18 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.